← Back to Search

Allograft Tissue

Nucel treatment group for Degenerative Disc Disease

N/A
Waitlist Available
Led By Pierce Nunley, MD
Research Sponsored by Organogenesis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial looks at whether a certain allograft tissue is safe and effective to use in lumbar interbody fusion procedures.

Eligible Conditions
  • Degenerative Disc Disease
  • Spondylolisthesis
  • Spondylosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fusion rate using non-contrast CT of the lumbar spine
Other outcome measures
Neurologic Exam
Oswestry Low Back Pain Disability Index
SF-12 health survey
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nucel treatment groupExperimental Treatment2 Interventions
One or two level lumbar interbody fusion surgery with Nucel

Find a Location

Who is running the clinical trial?

OrganogenesisLead Sponsor
35 Previous Clinical Trials
4,070 Total Patients Enrolled
Pierce Nunley, MDPrincipal InvestigatorSpine Institute of Louisiana
1 Previous Clinical Trials
135 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~21 spots leftby Apr 2025